Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681535 · ClinicalTrials.gov registry record · NA
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
A NA study of Diffuse Large B Cell Lymphoma, sponsored by Duke University.
- Active
- Registry status
- NA
- Development phase
- 241
- Enrollment target
- 12
- Study locations
NCT03681535 is a NA study of Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Duke University. The registered enrollment target is 241 participants, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (11% higher). The trial reports 12 study locations across 6 states.
The verdict
NCT03681535, a NA study of Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Duke University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 241 participants
- Enrollment target
- 12
- Study locations
Study Summary
This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab - containing chemotherapy.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (12)
Other
- University Hospital Motol - Prague
- University of Torino - Torino
- Juntendo University - Tokyo
- National Cancer Center of Singapore - Singapore
- Yonsei University Health System - Seoul
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital - Weymouth
Missouri
- Washington University School of Medicine - St Louis
New York
- University of Rochester James P. Wilmot Cancer Institute - Rochester
North Carolina
- Duke University Medical Center - Durham
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2019-02-13 |
| Est. Completion | 2028-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03681535
The ClinicalTrials.gov registry entry for NCT03681535 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (11% higher). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT03681535 reports 12 study locations spanning 6 distinct geographic areas - top geographies include Other, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT03681535 about?
NCT03681535 is a clinical study titled "Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma". This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining hi...
What is the current status of trial NCT03681535?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 241 participants. The study started on 2019-02-13. Estimated completion is 2028-07.
What conditions does trial NCT03681535 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT03681535?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03681535?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03681535 being conducted?
This trial has 12 study locations across Massachusetts, Missouri, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
RECRUITING · NA
-
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
RECRUITING · NA
-
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
ACTIVE NOT RECRUITING · NA
-
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · NA
-
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL
COMPLETED · NA
-
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.